Researchers from the Cell and Gene Therapy group and the Molecular diagnosis and Therapy group at Vall d’Hebron Institute of Research (VHIR), led by doctors Jordi Barquinero and Francisco Vidal respectively, have been awarded with one of the five "https://www.pfizer.es/noticia/cientificos_espanoles_reciben_premio_internacional_su_investigacion_tratamiento_hemofilia.html" ASPIRE Europe 2013 Hemophilia Research Prizes from the pharmaceutical company Pfizer. The project awarded, entitled “Development of a high-throughput platform for Hemophilia A drug screening and gene correction using induced pluripotent stem cells (iPSCs) from patients”, is going to analyze the production, processing, secretion and half-life of VIII coagulation factor in cells from hemophilia patients.Dr. Rafael Parra, director of the Division of Coagulopathies at Vall d’Hebron University Hospital and coordinator of the Hemophilia Unit at the same hospital, assures that one of the objectives of the project is “offering a new versatile tool for pharmaceutical research which could even open new doors towards individualized pharmacology”. Thanks to the economic support of this prize, Dr. Vidal assures that “the purchase and development of the new tool will provide basic knowledge that will enhance significant advances in the treatment of incurable diseases such as hemophilia". The study will start over the next months with the collaboration of specialists in reprogramming, generation of stem cells and gene therapy from VHIR and the "http://www.ibecbarcelona.eu/Noticies-IBEC/pfizer-award-for-ibecvall-dhebron-collaboration-on-hemophilia.html" Institute for Bioengineering of Catalonia. The ASPIRE Europe 2013 Hemophilia Research Prizes were born in 2011 to support basic and clinical research in hemophilia A and B and to facilitate the transfer of knowledge from the laboratory to the clinic.